



## THERE ARE 2 PAGES TO THIS FORM | ALL FIELDS ARE REQUIRED | PLEASE PRINT

This form must be completed and signed for <u>each</u> JUXTAPID prescription.

PATIENT INFORMATION			
First Name: Middle Initial: Address:	Last Name: Phone:		
City:	Email:		
State: Zip:	Date of Birth:		
JUXTAPID PRESCRIPTION			
Dose: mg po q hs (recommended starting dosage is 5 mg daily). Quantity to dispense: Refills: Additional Instructions:			
PRESCRIBER INFORMATION			
First Name: Middle Initial:  Practice/Facility Name:	Last Name:		
	Office Phone:		
Address:	Office Fax:		
City:	State License #:		
State: Zip:	NPI #:		

**CONTINUED ON NEXT PAGE** 

## PRESCRIBER ATTESTATION OF REMS REQUIREMENTS

- I understand that JUXTAPID is indicated only as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
- I affirm that my patient has a clinical or laboratory diagnosis consistent with HoFH.
- I have obtained and will continue to obtain the liver-related tests for this patient as directed in the JUXTAPID Prescribing Information.

Lab Testing Recommenda	ations				
Prior to initiating therapy – Measure ALT, AST, alkaline phosphatase, and total bilirubin.					
During the first year	<ul> <li>Measure liver-related tests (ALT and AST, at a minimum) monthly or prior to each increase in dose whichever occurs first.</li> </ul>				
After the first year	- Measure liver-related tests (ALT and AST, at a minimum) at least <b>every 3 months</b> and before any increase in dose.				
	,	' '	ransmitting this prescription to		
_	stitution Permitted	Dispense as Written	Date		
	Prior to initiating therapy  During the first year  After the first year  I authorize the JUXTAPID RE the appropriate pharmacy of	During the first year  - Measure liver-related increase in dose which increase in dose whic	Prior to initiating therapy — Measure ALT, AST, alkaline phosphatase, and total biliru  During the first year — Measure liver-related tests (ALT and AST, at a minimum increase in dose whichever occurs first.  After the first year — Measure liver-related tests (ALT and AST, at a minimum and before any increase in dose.  I authorize the JUXTAPID REMS Program to act on my behalf for the limited purposes of the appropriate pharmacy designated by the patient utilizing their benefit plan.		

**IMPORTANT** 

## REVIEW TO ENSURE ALL FIELDS ARE COMPLETED | RETURN BOTH PAGES

Fax this form to 1-855-898-2498 or scan and email it to REMS@chiesi.com.

If you have any questions, please contact the JUXTAPID REMS Coordinating Center.

Phone: 1-85-JUXTAPID (1-855-898-2743) | Fax: 1-855-898-2498 | www.juxtapidREMSprogram.com

